Search clinical trials for: Hydrochlorthiazide (HCTZ)

Total 556 results

Novartis

Completed

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

Hypertension

United States
VA Office of Research and Development

Completed

Diuretic Comparison Project (DCP)

Hypertension

United States, Puerto Rico
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Healthy
Merck Sharp & Dohme LLC

Completed

A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009)

Hypertension
Novartis

Completed

Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension

Hypertension

India
Novartis Pharmaceuticals

Terminated

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy (ARIA)

Non-diabetic Nephropathy

Netherlands
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

France, Poland, Ukraine, Germany, Spain, Bulgaria, Czechia
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

Belgium, Germany, Netherlands, Slovakia
Organon and Co

Completed

Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)

Hypertension
University of Maryland, Baltimore
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Salt Loading and Thiazide Intervention Study (SALTI)

Hypertension

United States
Novartis Pharmaceuticals

Terminated

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People (APOLLO)

Cardiovascular Events

Colombia, India, South Africa, Canada, Spain, Hungary, United States, Germany, Ireland, Argentina, Philippines, Brazil, Sweden, Malaysia, Chile, Israel, Czech Republic, Netherlands
Merck Sharp & Dohme LLC

Completed

Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)

Hypertension
University of Maryland, Baltimore
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer

Terminated

Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes

Metabolic Syndrome

United States
University of Kansas Medical Center

Recruiting

Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction (PASSION)

Hypertension | Chronic Pain | Diuretics Drug Reactions | SCS

United States
Novartis

Completed

Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension (ACQUIRE)

Hypertension

Switzerland, Italy, Argentina, Germany, Turkey, United States, Ecuador, Guatemala
University of New Mexico
University of Pittsburgh; Dialysis Clinic, Inc.

Terminated

Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes

Hypertension | Proteinuria | Type II Diabetes

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

Hypertension

United States
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan/ HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II

Healthy
Boehringer Ingelheim

Completed

Telmisartan Tab Hypertension

Hypertension
Boehringer Ingelheim

Completed

Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects

Healthy
AstraZeneca

Completed

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo

Hypertension

Russian Federation, Latvia, Romania, Slovakia, Belgium, Malta
Oregon Health and Science University
Oregon Clinical and Translational Research Institute

Completed

A Translational Approach to Gitelman Syndrome

Gitelman Syndrome

United States
Boehringer Ingelheim

Completed

An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension

Hypertension

Korea, Republic of
GlaxoSmithKline

Completed

Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions

Hypertension

South Africa
Novartis

Completed

A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

Hypertension

United States, Canada, Germany, Netherlands
Novartis Pharmaceuticals
Baker Heart and Diabetes Institute

Completed

Valsartan Intensified Primary Care Reduction of Blood Pressure Study (VIPER-BP)

Hypertension

United States, Australia
Boehringer Ingelheim

Completed

Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects

Healthy
Vanderbilt University Medical Center

Completed

Aldosterone and the Metabolic Syndrome

Glucose Metabolism Disorders | Metabolic Diseases | Diabetes Mellitus | Endocrine System Diseases

United States
Novartis

Completed

8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension

Hypertension

United States
Boehringer Ingelheim

Completed

Influence of Food on the Bioavailability of Two Doses of Telmisartan/HCTZ Fixed-dose Combination in Japanese Healthy Male Volunteers

Healthy
GlaxoSmithKline

Completed

A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension

Hypertension

United States, Canada, Germany, Russian Federation, France
Novartis

Completed

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

Hypertension

Sweden, United States, Romania, Denmark, Israel, Italy, Germany, Australia, Canada, Latvia, Lithuania, Turkey
Novartis

Completed

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension (EXALT)

Stage 2 Systolic Hypertension

United States
Novartis

Completed

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus (ASTRIDE)

Hypertension | Diabetes Mellitus

United States
Novartis

Completed

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension (ASCENT)

Hypertension

United States
Chiang Mai University

Unknown

Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study (NEB-HF)

Acute Kidney Injury | Acute Heart Failure

Thailand
Novartis

Completed

Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension (AMAZING)

Hypertension

Germany
Boehringer Ingelheim

Completed

Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5

Hypertension

France, Switzerland, Italy, Germany, Hong Kong, Netherlands, South Africa, Spain, Taiwan, Denmark, Sweden, Finland, Ireland, Korea, Republic of, Malaysia, Norway
Novartis Pharmaceuticals

Completed

Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans (ATLAAST)

Hypertension

United States
Profil Institut für Stoffwechselforschung GmbH

Completed

Empagliflozin and Sympathetic Nerve Traffic

Type 2 Diabetes Mellitus

Germany
Boehringer Ingelheim

Completed

Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension

Hypertension

Japan
Novartis Pharmaceuticals

Completed

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

Hypertension

United States
Takeda

Completed

Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.

Hypertension | Obesity

Germany
Merck Sharp & Dohme LLC
Pfizer

Completed

Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

Hypertension | Diabetes Mellitus, Type 2
Novartis

Completed

Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension

Hypertension

United States
Organon and Co

Terminated

A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)

Hypertension
William Beaumont Hospitals
Novartis Pharmaceuticals

Withdrawn

Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

Hypertension | Diabetes Type 2

United States

3

Subscribe